Premium
Therapeutic challenges in treating patients with fragile X syndrome and neoplasia
Author(s) -
Farach Andrew,
Farach Laura S.,
Paulino Arnold C.
Publication year - 2013
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24688
Subject(s) - medicine , fragile x syndrome , radiation therapy , blood cancer , intensive care medicine , toxicity , cancer , oncology , bioinformatics , psychiatry , biology
The administration of cytotoxic therapy to patients with fragile X syndrome (FXS) presents several unique therapeutic challenges. The existence of fragile sites poses a theoretical risk of tumorigenesis and potentially increased treatment associated toxicity, however, controversy exists. We review the 42 previously reported cases of neoplasia in patients with FXS and report two novel neoplasms in patients treated with radiation therapy or combined chemoradiation. Our experience suggests that radiation therapy can be delivered safely in these patients without an expectation for increased acute/sub‐acute normal tissue toxicity; however, treatment requires specialized facilities with the resources to deliver this care safely. Pediatr Blood Cancer 2013;60:E153–E156. © 2013 Wiley Periodicals, Inc.